Sandoz Bio100 Biosimilars Plan Targets 100 Products by 2040 and Doubles 2025 Sales by 2035

Novo Nordisk has stopped the two remaining ziltivekimab heart failure trials after a futility review, leaving ARTEMIS as the last anti-inflammatory cardiovascular outcomes bet. #SyenzaNews #MarketAccess #Cardiology #HTA

Aspen Pharmacare has walked away from local lenacapavir manufacturing over the lack of guaranteed volumes, and is instead backing Merck’s once-monthly oral PrEP pill, alimatravir. #SyenzaNews #HIV #PrEP #MarketAccess

Aspen Pharmacare posted 22% normalised earnings growth and is betting on a manufacturing rebound and a generic semaglutide rollout for FY2027. #SyenzaNews #Pharma #GLP1 #MarketAccess #SouthAfrica

Trump’s Most Favored Nation drug pricing policy is already delaying new medicine launches in Europe. Brussels journalist Christoffer Frendesen unpacks the silence, the data, and why it may outlast the Trump presidency. #SyenzaNews #MarketAccess #DrugPricing

US Medicare is paying for obesity GLP-1s for the first time, and more than 500,000 seniors signed up in the first two months. Our latest breaks down the $245 price, the $50 copay, and what it means for Lilly and Novo Nordisk. #SyenzaNews #MarketAccess #GLP1 #Medicare

EMA’s voluntary pre-submission pilot opens in September 2026. It adds earlier, more structured dialogue between applicants, rapporteurs and the Agency to curb premature filings. #SyenzaNews #MarketAccess #RegulatoryAffairs

Novartis and Bristol Myers Squibb have paused autoimmune CAR-T trials after inflammatory events and three deaths, putting the immune-reset thesis to its first real safety test. #SyenzaNews #CellTherapy #AutoimmuneDisease #MarketAccess

CTS’s Global Horizon panel brought four US operators to Montréal to explain why the US healthcare market rewards commercial readiness over good technology, and what founders can do about it. #SyenzaNews #MarketAccess #HealthTech

South Korea is putting AI at the centre of its healthcare agenda, pairing the new AI Basic Healthcare Strategy with a USD 30.4 billion biohealth export target. Vice Minister Lee Hyung Hoon sets out the vision in an interview with PharmaBoardroom. #SyenzaNews #SouthKorea #Biohealth #DigitalHealth #MarketAccess

The RECOVER-VITAL trial found nirmatrelvir-ritonavir offered no benefit for long COVID across cognitive, autonomic, or exercise symptoms. The study also shows why placebo controls matter: a large share of the placebo group improved on their own. #SyenzaNews #LongCOVID #ClinicalTrials #MarketAccess